4.3 Article

The treatment effect of rivaroxaban on clot characteristics in patients who present acutely with first time deep vein thrombosis

期刊

CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
卷 80, 期 2, 页码 139-151

出版社

IOS PRESS
DOI: 10.3233/CH-201030

关键词

Rivaroxaban; coagulation inhibitors; venous thrombosis; clot structure; biomarkers

资金

  1. Engineering and Physical Sciences research council (EPSRC) Healthcare Impact Partnership [EP/LO24799/01]
  2. EPSRC Platform Award [EP/NO13506/01]

向作者/读者索取更多资源

Rivaroxaban treatment has a protective effect against clot formation in DVT patients without significantly affecting clot microstructural properties.
BACKGROUND: The acute vascular disease deep vein thrombosis (DVT) requires oral anticoagulants to prevent progression. Monitoring therapeutic efficacy of direct oral anticoagulants (DOAC), including rivaroxaban, is problematic as no reliable test is available. Advances in rheometry have led to the development of a functional coagulation biomarker using Gel Point (GP) analysis which assesses clot structure formation. The biomarker measures incipient clot formation time (T-GP) and quantifies fibrin clot structure in terms of fractal dimension (d(f)). OBJECTIVE: This study aimed to investigate clot structure formation in first time DVT and the effect of rivaroxaban treatment. METHODS: This prospective observational cohort study measured the GP and standard laboratory markers at three sample points: pre-treatment and at 20 and 60 days following 15 mg BD and 20 mg OD rivaroxaban respectively. RESULTS: Forty DVT patients (mean age 64 years [SD +/- 14.8]; 23 males, 17 female) were recruited. The results show that DVT vs non-DVT patients did not have a significantly different GP profile (d(f): 1.72 +/- 0.06 vs 1.70 +/- 0.06 and T-GP: 267 +/- 68 sec vs 262 +/- 73 sec) with both within the defined healthy index. In addition, rivaroxaban therapy increased T-GP to 392 s (+/- 135 s) after 20 days, and subsequently increased to 395 s (+/- 194 s) at 60 days but did not significantly increase d(f) (from 1.69 +/- 0.05 to 1.71 +/- 0.06). CONCLUSIONS: The results indicate in this cohort of DVT patients there was no underlying hypercoagulable effect as determined by gel point analysis. Furthermore, the anticoagulant effect of rivaroxaban prolonged clotting, suggesting a protective effect against clot formation, without significantly reducing clot microstructural properties.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据